TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: maximum inspiratory pressures
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: maximum expiratory pressures
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: cessation success
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Objective sleep improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Subjective sleep quality improvement
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Proportion of women who had a clinical breast examination or mammogram
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Overutilization of laboratory tests
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Underutilization of laboratory tests
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Cost of unnecessary tests
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Diagnostic success of non-cardiac MRI
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Diagnostic success of cardiac MRI in cPM-carriers
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Diagnostic success of cardiac MRI in cICD-carriers
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Days off school
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Visits to a doctor for asthma
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Reports of poor health
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Recognition of lunate necrosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Decreased blood calcium levels
Endpoint domain: Adverse events/effects
Primary endpoint: Decrease in UCDAI
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: IHCL content
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: VLDL-triglyceride concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Percentage of youths remaining sexually inexperienced one year later
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Percentage of youths using a condom after initiating sex
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: KOOS pain sub-scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: serum programmed death 1 (PD-1) concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: grey matter volume in the medial orbital prefrontal cortex
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: AUC24h
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ΔUGE24h
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Effectiveness of 1% PAA for removal of CH
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Reduction in bacterial load on the tongue
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Serum levels of triglycerides (TG)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Serum levels of high-density lipoprotein (HDL)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Blood viscosity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Plasma AA level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: first-time performance assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: learning curve assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: balance and gait performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Lower HbA(1c) at 24 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Percentage of patients reaching HbA(1c) < 7.0%
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Incidence of severe hypoglycaemia
Endpoint domain: Adverse events/effects
Primary endpoint: Nasal obstruction control
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Nasal discharge control
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Recurrent adenomas
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Cerebral and ocular blood flow velocity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: satisfaction with surgery results
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: MUAC in mothers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nutritional outcomes
Primary endpoint: WAZ in infants and children
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nutritional outcomes
Primary endpoint: HAZ in infants and children
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nutritional outcomes
Primary endpoint: Change in Agatston CAC score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Increase in calcification scores in the aortic valve
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Reductions in serum parathyroid hormone, calcium and phosphorus levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Time spent on outpatient visit
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Convenience of electronic assessment
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Cost of electronic assessment
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Levels of anxiety and depression at six months follow-up
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Cycle pregnancy rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Reduction in total body fat
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Increase in perceived fullness
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: AAI index as an indicator of consciousness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Episodes of too low anesthesia
Endpoint domain: Adverse events/effects
Primary endpoint: mean denture plaque scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: new bleeding episodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: amount of interferon‐alpha receptor mRNA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Recurrence-Free Survival (RFS) at 10 years
Endpoint domain: Mortality/survival
Primary endpoint: Detection rates of periodontal pathogens
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Total Testosterone (TT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: New lesions occurrence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Accuracy of hypertension diagnostic methods
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Higher offspring 5-y fat-free mass
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of Worsening Renal Function (WRF)
Endpoint domain: Adverse events/effects
Primary endpoint: Bilateral forearm blood flow response to vasodilators
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Plasma tissue plasminogen activator levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Language recovery
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Participation rate in Tai Chi vs conventional group
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Improvement of anxiety, depression and physical well-being
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: 60-day mortality or cardiovascular/renal hospitalization
Endpoint domain: Mortality/survival
Primary endpoint: ADC and FA values
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: MAT/TT index normalization
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: marginal discoloration at the enamel margins
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in arachidonate levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in linoleate levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in n-3 fatty acids levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: QIDS-SR score improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Overall adherence to prescribed evidence-based drugs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Impairment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Roland‐Morris disability score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: HIV-1 RNA level reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Accuracy of force estimation during isometric resistance exercise
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Completion of the intervention as per protocol
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Participants' confidence and motivation to exercise
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Success rate of PLMA insertion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Time taken for successful placement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Number of patients with hypovolemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean minimum Scvo₂
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bone mineral density (BMD) increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: No emetic episodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Antiemetic treatment failures
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Oxford Elbow Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: sleep efficiency (SE)
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: 3-yr weight change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to return to good signals after disturbance by electric cautery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma endothelin levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: fetal deaths
Endpoint domain: Mortality/survival
Primary endpoint: low birthweight
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: severe preterm birth
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: small size for gestational age
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: T-cell counts (CD4, CD8, CD3)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: cumulative penetration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 0-6 h post-dose WM FEV1
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Relief of central poststroke pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: VAS scores for facial appearance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: HADS scores for depressive symptoms
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Exacerbations of asthma symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prebronchodilator forced expiratory volume in one second (FEV1)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Geometric mean concentration of methacholine causing a 20% fall in FEV1 (PC20)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Reliability of palpation accuracy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of unprotected sex occasions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Satisfaction with HR-VG
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: overall impairment scores for driving
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: signaling adherence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Unbalanced proximal contacts
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Absence of occlusal contacts
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Vertigo VAS score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: spatial working memory improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: cognitive function deterioration
Endpoint domain: Adverse events/effects
Primary endpoint: Loss of hepatitis B e antigen (HBeAg) in serum
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sustained suppression of serum hepatitis B virus (HBV) DNA to undetectable levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: length of stay in intensive care unit
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: incisional pain
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Difference in DFDs
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: EMGdia under spontaneous breathing
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Severity of pain symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: New clinical diagnoses of PTSD/Depression
Endpoint domain: Adverse events/effects
Primary endpoint: Sensitivity of HbA(1c) ≥ 6.5% as a diagnostic criterion for Type 2 diabetes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Enoxaparin clearance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Risk of all haemorrhagic events
Endpoint domain: Adverse events/effects
Primary endpoint: Risk of major haemorrhagic events
Endpoint domain: Adverse events/effects
Primary endpoint: End tidal carbon dioxide
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Total physical activity time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients with PGA-C clear or almost clear and ≥2 grade improvement from baseline at Week 8
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in pruritus vs vehicle
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Major depression
Endpoint domain: Adverse events/effects
Primary endpoint: PTSD
Endpoint domain: Adverse events/effects
Primary endpoint: Conduct disorder
Endpoint domain: Adverse events/effects
Primary endpoint: Median FACES scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Use of opioid medications
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Use of nonopioid medications
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Adjusted blood level of calcium
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: motor skill gains
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: use
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: movement quality
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Probability of bleeding
Endpoint domain: Adverse events/effects
Primary endpoint: Tenofovir monoester Cmax
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC0-4 of tenofovir monoester
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Readmission within 30 days
Endpoint domain: Mortality/survival
Primary endpoint: neonatal jaundice
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: maternal hemorrhage at birth
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: phototherapy rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Positive PASS
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Expansion of gp100-specific CD8(+) T cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: rate of bone loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: bone turnover
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: incidence of bacteremia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: concentration of systemic endotoxin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: incidence of intra-abdominal abscess
Endpoint domain: Adverse events/effects
Primary endpoint: Number of CGA-positive cells/cm(2)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Proportion of NE-positive tumors
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Fall in specific airway conductance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: narcotic drug intake
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: incidence of throat infection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Average CRP levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Cost of Transport (CoTvert)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: UAS assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: average weekly walking METs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: detrusor leak point pressure changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: hydroureter improvement rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: hydronephrosis improvement rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Body Mass
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: average daily increase of oral intake
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: apical pulse rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: MVV (Mean Venous Velocity)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Borg score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: 10-year prostate specific antigen relapse-free survival
Endpoint domain: Mortality/survival
Primary endpoint: microvascular function improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Maximal oxygen consumption (V·O 2max)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Muscle insulin receptor expression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: self-reported bonding
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: change in peak power
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Perceived competence to exercise regularly
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Relations with parents
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Adolescent externalizing and internalizing symptomatology
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Clustering of overweight-related cardiometabolic risk factors
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes